PIRS - ピエリス・ファ―マシュ―ティカルズ (Pieris Pharmaceuticals Inc.)

PIRSのニュース

   Stock Mover: Ashford Hospitality Trust, Inc. (NYSE:AHT), Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS)  2021/07/12 23:06:23 Stock Equity
Ashford Hospitality Trust, Inc. (AHT) with the stream of 1.51% also noticed, India Pieris Pharmaceuticals, Inc. (PIRS) encountered a rapid change of -1.04% in the last hour of Mondays trading The post Stock Mover: Ashford Hospitality Trust, Inc. (NYSE:AHT), Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) appeared first on Stocks Equity .
   ITM Appoints Dr. Sabine Daugelat as Chief Operating Officer  2021/07/06 09:00:00 Business Wire
GARCHING & MUNICH, Germany--(BUSINESS WIRE)--ITM AG, a leading radiopharmaceutical biotech company, today announced the appointment of Dr. Sabine Daugelat to its management team as Chief Operating Officer (COO) of the clinical development of ITM. Dr. Daugelat has over 18 years of experience in the pharmaceutical and biotechnology industry and was most recently Executive Director, Head of Project Leadership at Pieris Pharmaceuticals. In her role at ITM, she will be responsible for the operationa
   This Risky Micro-Cap Could Pay Off Big  2021/06/30 12:31:00 The Motley Fool
Pieris Pharmaceuticals is introducing a whole new class of drugs to the marketplace.
   Pieris Pharmaceuticals Shares Rise 19% After Getting Orphan Drug Status  2021/06/30 02:28:51 MarketWatch
Pieris Pharmaceuticals Shares Rise 19% After Getting Orphan Drug Status MarketWatch
   Pieris Pharma stock soars 17% on development plans for PRS-220 in lung disease; secures $17M grant  2021/06/25 11:28:44 Seeking Alpha
   Thinking about buying stock in G1 Therapeutics, Strongbridge Biopharma, Soligenix, Pieris Pharmaceuticals, or Diffusion Pharmaceuticals?  2021/02/16 13:31:00 PR Newswire
NEW YORK, Feb. 16, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GTHX, SBBP, SNGX, PIRS, and DFFN. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   Pieris Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update - Stocks News Feed  2020/11/04 12:39:11 Stocks News Feed
Share this Stock InformationCOMPANY TO HOST AN INVESTOR CONFERENCE CALL ON WEDNESDAY, NOVEMBER 4, 2020 AT 8:00 AM EST PRS-060/AZD1402 first regulatory submission for global phase 2a study has been made; site initiation and patient screening expected this year PRS-343 in-use studies requested by FDA are completed; forthcoming meeting with FDA to align on path… Read More »Pieris Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update
   Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Expected to Announce Quarterly Sales of $8.99 Million  2020/10/24 12:14:43 The Olympia Report
Analysts forecast that Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) will report sales of $8.99 million for the current fiscal quarter, Zacks reports. Two analysts have made estimates for Pieris Pharmaceuticals’ earnings. The lowest sales estimate is $7.50 million and the highest is $10.47 million. Pieris Pharmaceuticals reported sales of $15.13 million in the same quarter last year, […]
   Pieris Pharmaceuticals (NASDAQ:PIRS) Stock Price Up 5%  2020/10/21 10:36:50 Zolmax News
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS)’s share price rose 5% during mid-day trading on Monday . The stock traded as high as $2.53 and last traded at $2.50. Approximately 558,991 shares changed hands during trading, an increase of 20% from the average daily volume of 467,441 shares. The stock had previously closed at $2.38. A number of […]
   Zacks: Brokerages Anticipate Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Will Post Quarterly Sales of $8.99 Million  2020/10/21 01:46:44 US Banking News
Equities research analysts forecast that Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) will post sales of $8.99 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Pieris Pharmaceuticals’ earnings. The lowest sales estimate is $7.50 million and the highest is $10.47 million. Pieris Pharmaceuticals reported sales of $15.13 million during […]
   Thinking about buying stock in G1 Therapeutics, Strongbridge Biopharma, Soligenix, Pieris Pharmaceuticals, or Diffusion Pharmaceuticals?  2021/02/16 13:31:00 PR Newswire
NEW YORK, Feb. 16, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GTHX, SBBP, SNGX, PIRS, and DFFN. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   Pieris Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update - Stocks News Feed  2020/11/04 12:39:11 Stocks News Feed
Share this Stock InformationCOMPANY TO HOST AN INVESTOR CONFERENCE CALL ON WEDNESDAY, NOVEMBER 4, 2020 AT 8:00 AM EST PRS-060/AZD1402 first regulatory submission for global phase 2a study has been made; site initiation and patient screening expected this year PRS-343 in-use studies requested by FDA are completed; forthcoming meeting with FDA to align on path… Read More »Pieris Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update
   Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Expected to Announce Quarterly Sales of $8.99 Million  2020/10/24 12:14:43 The Olympia Report
Analysts forecast that Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) will report sales of $8.99 million for the current fiscal quarter, Zacks reports. Two analysts have made estimates for Pieris Pharmaceuticals’ earnings. The lowest sales estimate is $7.50 million and the highest is $10.47 million. Pieris Pharmaceuticals reported sales of $15.13 million in the same quarter last year, […]
   Pieris Pharmaceuticals (NASDAQ:PIRS) Stock Price Up 5%  2020/10/21 10:36:50 Zolmax News
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS)’s share price rose 5% during mid-day trading on Monday . The stock traded as high as $2.53 and last traded at $2.50. Approximately 558,991 shares changed hands during trading, an increase of 20% from the average daily volume of 467,441 shares. The stock had previously closed at $2.38. A number of […]
   Zacks: Brokerages Anticipate Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Will Post Quarterly Sales of $8.99 Million  2020/10/21 01:46:44 US Banking News
Equities research analysts forecast that Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) will post sales of $8.99 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Pieris Pharmaceuticals’ earnings. The lowest sales estimate is $7.50 million and the highest is $10.47 million. Pieris Pharmaceuticals reported sales of $15.13 million during […]

calendar